Novo Holdings A/S Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001388325

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 25 positions · Total reported value $1.72B · Top-10 concentration 73.5% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 40.7% · 2 new · 8 cut · 1 exited

Active Share (vs S&P 500): 99.7% · vs QQQ: 99.3% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -12.9% · vs SPY -15.1% · Prev Value $1.72B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -0.6% · vs SPY -2.8% · Latest Value $1.49B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2026 13F filing, Novo Holdings A/S disclosed 25 equity positions with a combined reported value of $1.72B. The filing implies a focused portfolio: its ten largest positions account for 73.5% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were EWTX ($217.37M), ASML ($188.89M), COAG ($153.55M). By sector, the heaviest allocations are Health Care 69.2%, Technology 15.0%. Versus the prior quarter, allocation shifted toward Health Care (+7.4pp), Consumer Discretionary (+1.6pp) and away from Technology (-1.3pp), Real Estate (-2.8pp).

Versus the prior quarter, Novo Holdings A/S opened 2 new positions, trimmed 8 and fully exited 1, a turnover rate of 40.7% of positions. The portfolio's overlap with the prior quarter was 68% of names.

The largest new positions opened in Q2 2026 were COAG ($153.55M), AVLN ($127.84M), FND ($47.31M).

Of the 1 positions fully exited versus the prior quarter, the largest were APGE ($37.88M), BMRN ($37.28M), VALN ($6.61M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • COAG HEMAB THERAPEUTICS HLDGS INC · $153.55M
  • AVLN AVALYN PHARMACEUTICALS INC · $127.84M
  • FND FLOOR & DECOR HLDGS INC · $47.31M
  • ALMS ALUMIS INC · $30.95M
  • DYN DYNE THERAPEUTICS INC · $21.33M
  • INSM INSMED INC · $12.87M

Fully Exited (vs previous quarter)

  • APGE APOGEE THERAPEUTICS INC · prev qtr: $37.88M
  • BMRN BIOMARIN PHARMACEUTICAL INC · prev qtr: $37.28M
  • VALN VALNEVA SE · prev qtr: $6.61M

Insider Transactions (Form 4)

Latest Novo Holdings A/S buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-05-04 Conversion Hemab Therapeutics Holdings, Inc. 4,180,550 — SEC filing
2026-05-01 Buy Avalyn Pharma Inc. 555,555 $18.00 SEC filing
2026-05-01 Conversion Avalyn Pharma Inc. 3,327,734 — SEC filing

All insider transactions →

Fund Profile

Novo Holdings A/S files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 26 positions worth $1.49B in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Portfolio Structure

  • 26 positions · $1.49B reported value (Q3 2026)
  • Top 10 holdings = 76.1% of reported value
  • Largest position: EWTX (EDGEWISE THERAPEUTICS INC) at 14.6%
  • Average position size: $57.30M

Sector Tilt

  • Health Care 67.0%
  • Information Technology 17.7%
  • Real Estate 10.9%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 2 new, 6 added, 8 reduced, 1 exited
  • 10 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund appears to be maintaining a cautious stance, with a focus on health care, which is traditionally seen as a defensive sector. The addition of new positions and minor adjustments to existing ones suggest a belief in the potential for growth in the health care sector, while also maintaining a diversified portfolio to mitigate risk. 2. Key Moves: - Added: HEMAB THERAPEUTICS HOLDINGS (COAG) and AVALYN PHARMA INC (AVLN), indicating a new interest in biotechnology. - Reduced: MIRUM PHARMACEUTICALS INC (MIRM), ARRIVENT BIOPHARMA INC (AVBP), and ENLIVEN THERAPEUTICS INC (ELVN), which may reflect a reassessment of these companies' prospects or a strategic shift away from certain biotech companies. - No Change: Most positions remained stable, with the exception of MIRM, which saw a significant reduction. 3. Portfolio Structure: - Passive/Active: The portfolio seems to lean towards a passive approach, with a high number of holdings that are unchanged from the previous quarter. - Sector Bias: The fund has a strong bias towards health care, with a total of 6 out of 10 top holdings in this sector. - Risk Appetite: The risk appetite appears moderate, with no aggressive additions or reductions in high-risk sectors. 4. Per-Holding One-Liner: - EWTX: EdgeWise Therapeutics, a biotechnology company focusing on novel treatments for cancer. - ASML: ASML Holding, a leading provider of chipmaking equipment. - COAG: Hemab Therapeutics, a biotechnology company developing therapies for hemophilia and other bleeding disorders. - BN: Brookfield Corporation, a global real estate and infrastructure company. - MPLT: Maplight Therapeutics, a biotechnology company focusing on cancer immunotherapy. - MIRM: Mirum Pharmaceuticals, a biopharmaceutical company focused on rare genetic disorders. - AVLN: Avalyn Pharma, a biotechnology company developing therapies for orphan diseases. - CRM: Salesforce, a customer relationship management software provider. - AVBP: Arrivant Biopharma, a biopharmaceutical company focused on rare genetic diseases. - ELVN: Enliven Therapeutics, a biotechnology company developing treatments for metabolic diseases. 5. One-Sentence Style Summary: Novo Holdings A/S maintained a conservative approach with a focus on health care, adding new biotech positions while reducing exposure to some pharmaceuticals, reflecting a balanced risk-adjusted strategy.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 69.2%
Technology 15.0%
Other 2.9%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 5.35M $217.37M 12.62%
12.62%
Hold
2 94.95K $188.89M 10.97%
10.97%
Hold
3 4.18M $153.55M 8.92%
8.92%
New
4 3.50M $149.53M 8.68%
8.68%
Hold
5 3.69M $132.13M 7.67%
7.67%
Hold
6 1.12M $131.70M 7.65%
7.65%
Reduce
7 3.88M $127.84M 7.42%
7.42%
New
8 393.19K $61.60M 3.58%
3.58%
Hold
9 1.50M $52.11M 3.03%
3.03%
Reduce
10 1.00M $50.75M 2.95%
2.95%
Reduce
11 1.32M $49.39M 2.87%
2.87%
Reduce
12 1.40M $48.41M 2.81%
2.81%
Reduce
13 797.00K $47.31M 2.75%
2.75%
New
14 800.00K $46.50M 2.70%
2.70%
Reduce
15 3.25M $43.21M 2.51%
2.51%
Reduce
16 2.13M $39.22M 2.28%
2.28%
Add
17 1.02M $38.14M 2.21%
2.21%
Reduce
18 1.10M $30.95M 1.80%
1.80%
New
19 485.44K $29.30M 1.70%
1.70%
Hold
20 257.33K $24.70M 1.43%
1.43%
Hold
21 960.39K $21.33M 1.24%
1.24%
New
22 2.25M $17.14M 1.00%
1.00%
Add
23 120.72K $12.87M 0.75%
0.75%
New
24 441.56K $7.17M 0.42%
0.42%
Hold
25 158.15K $1.08M 0.06%
0.06%
Hold

FAQ

What did Novo Holdings A/S buy in 2026-Q2?

In its 2026-Q2 13F filing, Novo Holdings A/S reported 25 equity positions worth $1.72B in aggregate; its largest disclosed positions were EWTX ($217.37M), ASML ($188.89M), COAG ($153.55M).

How large is Novo Holdings A/S's portfolio?

Novo Holdings A/S reported $1.72B of long equity holdings across 25 positions as of 2026-Q2. Top-10 holdings account for 73.5% of reported value.

What is Novo Holdings A/S's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/novo-holdings-a-s/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →